| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | N/A |
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
http://www.zacks.com/stock/news/539107/abbvie-abbv-gets-fda-nod-for-label-expansion-of-hcv-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539107
Sep 27, 2019 - AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
0
IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-539102
Sep 27, 2019 - IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.
0
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
http://www.zacks.com/stock/news/537152/heres-why-sanofi-sny-is-outperforming-its-industry-of-late?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-537152
Sep 26, 2019 - Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
0
Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
http://www.zacks.com/stock/news/537068/tyme-initiates-pivotal-stage-of-pancreatic-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-537068
Sep 26, 2019 - Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.
0
Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose
http://www.zacks.com/stock/news/535522/bristol-myers-opdivo-gains-positive-chmp-view-for-new-dose?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-535522
Sep 25, 2019 - Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.
0
5 Top Dow Stocks to Buy on the Dip for a Stronger Portfolio
http://www.zacks.com/stock/news/535218/5-top-dow-stocks-to-buy-on-the-dip-for-a-stronger-portfolio?cid=CS-ZC-FT-analyst_blog|investment_ideas-535218
Sep 25, 2019 - A fundamentally stable U.S. economy, which is growing for history setting 11 years, albeit at a slow pace and a dovish Fed in 2019 are the two major drivers of the Dow.
0
Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
http://www.zacks.com/stock/news/533719/clovis-gains-rights-to-pre-clinical-cancer-program-for-%2412m?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-533719
Sep 24, 2019 - Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
0
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532006
Sep 23, 2019 - Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
0
Merck's Two HIV Drugs Get FDA Approval for Expanded Use
http://www.zacks.com/stock/news/531985/mercks-two-hiv-drugs-get-fda-approval-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-531985
Sep 23, 2019 - Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
0
Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
http://www.zacks.com/stock/news/531920/pfizers-bavencio-gets-chmp-recommendation-for-first-line-rcc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-531920
Sep 23, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
0